Top-Rated StocksTop-RatedNASDAQ:PRTA Prothena (PRTA) Stock Forecast, Price & News $69.01 +2.62 (+3.95%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$66.37▼$69.0850-Day Range$47.66▼$78.5952-Week Range$21.06▼$79.65Volume436,735 shsAverage Volume484,957 shsMarket Capitalization$3.64 billionP/E RatioN/ADividend YieldN/APrice Target$86.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Prothena MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside25.1% Upside$86.33 Price TargetShort InterestBearish6.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 6 Articles This WeekInsider TradingSelling Shares$15.09 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.98) to ($4.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector364th out of 983 stocksPharmaceutical Preparations Industry170th out of 486 stocks 3.4 Analyst's Opinion Consensus RatingProthena has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $86.33, Prothena has a forecasted upside of 25.1% from its current price of $69.01.Amount of Analyst CoverageProthena has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.09% of the outstanding shares of Prothena have been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Prothena has recently decreased by 1.83%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTA. Previous Next 2.0 News and Social Media Coverage News SentimentProthena has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Prothena this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for PRTA on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Prothena to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,088,550.00 in company stock.Percentage Held by Insiders28.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.72% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prothena are expected to decrease in the coming year, from ($3.98) to ($4.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -26.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -26.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProthena has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Prothena (NASDAQ:PRTA) StockProthena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.Read More Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTA Stock News HeadlinesJune 2, 2023 | benzinga.comProthena to Participate in Jefferies 2023 Healthcare ConferenceJune 1, 2023 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Insider Michael J. Malecek Sells 5,000 Shares of StockJune 3, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 22, 2023 | americanbankingnews.comProthena (NASDAQ:PRTA) Now Covered by Analysts at StockNews.comMay 20, 2023 | americanbankingnews.comInsider Selling: Prothena Co. plc (NASDAQ:PRTA) CEO Sells 45,000 Shares of StockMay 20, 2023 | americanbankingnews.comInsider Selling: Prothena Co. plc (NASDAQ:PRTA) CFO Sells $7,029,050.00 in StockMay 17, 2023 | msn.comProthena adds former FDA neuro chief Billy Dunn to director boardMay 16, 2023 | finance.yahoo.comProthena Announces Appointment of Billy Dunn, M.D., to its Board of DirectorsJune 3, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 16, 2023 | msn.comLooking Into Prothena Corp's Return On Capital EmployedMay 12, 2023 | seekingalpha.comCORPORATE OVERVIEWMay 12, 2023 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 10, 2023 | benzinga.comLooking At Prothena Corp's Recent Unusual Options ActivityMay 10, 2023 | finance.yahoo.comProthena Corporation plc (NASDAQ:PRTA) Analysts Just Trimmed Their Revenue Forecasts By 29%May 8, 2023 | americanbankingnews.comProthena (NASDAQ:PRTA) Price Target Raised to $120.00May 8, 2023 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Director Sells $855,000.00 in StockMay 7, 2023 | seekingalpha.comProthena Biosciences' Unique Approach To Protein Misfolding Could Be The FutureMay 7, 2023 | americanbankingnews.comProthena (NASDAQ:PRTA) Trading 11.6% Higher Following Analyst UpgradeMay 6, 2023 | americanbankingnews.comProthena (NASDAQ:PRTA) Price Target Raised to $90.00 at HC WainwrightMay 5, 2023 | americanbankingnews.comProthena (NASDAQ:PRTA) Shares Gap Up to $52.51May 5, 2023 | finance.yahoo.comProthena (PRTA) Reports Q1 Loss, Lags Revenue EstimatesApril 29, 2023 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Insider Michael J. Malecek Sells 5,000 SharesApril 28, 2023 | americanbankingnews.comBrokers Issue Forecasts for Prothena Co. plc's Q1 2023 Earnings (NASDAQ:PRTA)April 26, 2023 | americanbankingnews.comProthena (NASDAQ:PRTA) Given Outperform Rating at SVB LeerinkApril 26, 2023 | americanbankingnews.comProthena (NASDAQ:PRTA) Rating Reiterated by SVB LeerinkApril 26, 2023 | americanbankingnews.comProthena (NASDAQ:PRTA) Coverage Initiated by Analysts at SVB SecuritiesApril 22, 2023 | americanbankingnews.comInsider Selling: Prothena Co. plc (NASDAQ:PRTA) CAO Sells 5,000 Shares of StockSee More Headlines PRTA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTA Company Calendar Last Earnings5/04/2023Today6/02/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTA CUSIPN/A CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees82Year FoundedN/APrice Target and Rating Average Stock Price Forecast$86.33 High Stock Price Forecast$120.00 Low Stock Price Forecast$55.00 Forecasted Upside/Downside+25.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,950,000.00 Net Margins-232.19% Pretax Margin-250.21% Return on Equity-24.99% Return on Assets-19.59% Debt Debt-to-Equity RatioN/A Current Ratio14.33 Quick Ratio14.33 Sales & Book Value Annual Sales$54.92 million Price / Sales66.28 Cash FlowN/A Price / Cash FlowN/A Book Value$11.51 per share Price / Book6.00Miscellaneous Outstanding Shares52,752,000Free Float37,876,000Market Cap$3.64 billion OptionableOptionable Beta0.36 Key ExecutivesGene G. KinneyPresident, Chief Executive Officer & DirectorBrandon S. SmithChief Operating OfficerTran B. NguyenChief Financial & Strategy OfficerWagner M. ZagoChief Scientific OfficerHideki GarrenChief Medical OfficerKey CompetitorsBlueprint MedicinesNASDAQ:BPMCUltragenyx PharmaceuticalNASDAQ:RAREReata PharmaceuticalsNASDAQ:RETAArrowhead PharmaceuticalsNASDAQ:ARWRCytokineticsNASDAQ:CYTKView All CompetitorsInsiders & InstitutionsMichael J. MalecekSold 5,000 sharesTotal: $323,200.00 ($64.64/share)ProShare Advisors LLCSold 469 shares on 5/26/2023Ownership: 0.016%Putnam Investments LLCSold 14,489 shares on 5/22/2023Ownership: 0.097%Ameriprise Financial Inc.Sold 12,168 shares on 5/22/2023Ownership: 0.023%Karin L. WalkerSold 5,000 sharesTotal: $370,000.00 ($74.00/share)View All Insider TransactionsView All Institutional Transactions PRTA Stock - Frequently Asked Questions Should I buy or sell Prothena stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRTA shares. View PRTA analyst ratings or view top-rated stocks. What is Prothena's stock price forecast for 2023? 9 Wall Street analysts have issued 1 year price objectives for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $120.00. On average, they predict the company's stock price to reach $86.33 in the next twelve months. This suggests a possible upside of 25.1% from the stock's current price. View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts. How have PRTA shares performed in 2023? Prothena's stock was trading at $60.25 at the start of the year. Since then, PRTA shares have increased by 14.5% and is now trading at $69.01. View the best growth stocks for 2023 here. When is Prothena's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our PRTA earnings forecast. How were Prothena's earnings last quarter? Prothena Co. plc (NASDAQ:PRTA) issued its quarterly earnings data on Thursday, May, 4th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.06. The biotechnology company had revenue of $2.17 million for the quarter, compared to analysts' expectations of $7.53 million. Prothena had a negative trailing twelve-month return on equity of 24.99% and a negative net margin of 232.19%. Prothena's revenue for the quarter was up 88.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.78) earnings per share. What ETFs hold Prothena's stock? ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD). What is Prothena's stock symbol? Prothena trades on the NASDAQ under the ticker symbol "PRTA." Who are Prothena's major shareholders? Prothena's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (12.82%), BlackRock Inc. (6.87%), Price T Rowe Associates Inc. MD (6.07%), Wellington Management Group LLP (4.30%), State Street Corp (3.99%) and Palo Alto Investors LP (3.15%). Insiders that own company stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen and Wagner M Zago. View institutional ownership trends. How do I buy shares of Prothena? Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Prothena's stock price today? One share of PRTA stock can currently be purchased for approximately $69.01. How much money does Prothena make? Prothena (NASDAQ:PRTA) has a market capitalization of $3.64 billion and generates $54.92 million in revenue each year. The biotechnology company earns $-116,950,000.00 in net income (profit) each year or ($2.62) on an earnings per share basis. How can I contact Prothena? Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510. This page (NASDAQ:PRTA) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.